Struggling From Price Cuts, Korea’s Dong-A Looks To Change Course
This article was originally published in PharmAsia News
Executive Summary
Korea’s top pharma company saw flat sales and a drop in profits in the third quarter, showing the impact of industry-wide price cuts. GSK holds a 10% stake in Dong-A.